<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206384</url>
  </required_header>
  <id_info>
    <org_study_id>005-00036-8</org_study_id>
    <nct_id>NCT04206384</nct_id>
  </id_info>
  <brief_title>Low-Frequency, High-Intensity Ultrasound for Waist Circumference Reduction</brief_title>
  <official_title>Efficacy of Low-Frequency, High-Intensity Ultrasound for Reduction in Subdermal Adipose Layers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAO Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAO Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness and safety of externally applied lower frequency&#xD;
      ultrasound to the waist/abdominal region of adults to achieve a reduction of fat&#xD;
      cells/tissues below the skin, evidenced by a reduction in patient waist circumference.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate principally the effectiveness, and secondarily the safety, of&#xD;
      external application of lower frequency ultrasound to the waist/abdominal region of adults to&#xD;
      achieve a reduction of adipose cells/tissues in the subcutaneous region. The application of&#xD;
      higher frequency (200kHz to 3MHz) ultrasound for this purpose has previously been&#xD;
      demonstrated and such devices have received clearance for treatment in the United States. The&#xD;
      question remains whether application of ultrasound at a lower frequency (35kHz to 45kHz) can&#xD;
      achieve comparable results without introducing any new or elevated risks to the patient. This&#xD;
      study will apply 3 treatments of the ultrasound energy and evaluate the change in patient's&#xD;
      waist circumference, which would be evidence of reducing sub-cutaneous adipose cells/tissues.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Actual">May 12, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Treatment Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Waist Circumference Change</measure>
    <time_frame>The difference between the circumference measurement immediately prior to the first treatment (Baseline) to immediately after the 4-week follow-up assessment (approximately 6 weeks from Baseline).</time_frame>
    <description>Change in measurable circumference of the patient's abdominal area from Baseline to immediately after the 4-week follow-up assessment (approximately 6 weeks from Baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pain</measure>
    <time_frame>Assessed during and immediately after (up to 15 minutes after use ceased) each application of the device, and at 1 week, 4 weeks, and 12 weeks post-treatment.</time_frame>
    <description>Incidence of pain during each application of the device and/or immediately following each application of the device (up to 15 minutes after use of the device ceased).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Abdominal Subcutaneous Fat</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Ultimate Contour Body Sculpting Device</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal to or above 18&#xD;
&#xD;
          -  Body Mass Index â‰¥ 25.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age equal to or below 17.&#xD;
&#xD;
          -  Body Mass Index &lt; 25.&#xD;
&#xD;
          -  Open sores, wounds, or otherwise compromised skin in the treatment area&#xD;
&#xD;
          -  History of keloid formation, hypertrophic scarring, or abnormal/delayed wound healing.&#xD;
&#xD;
          -  Known or suspected pregnancy, or active nursing.&#xD;
&#xD;
          -  General systemic conditions of arteriosclerosis, anemia, aortic aneurysm, or&#xD;
             hypertension.&#xD;
&#xD;
          -  Liver conditions such as hyperlipidemia, hepatitis, liver disease, or abnormal liver&#xD;
             function.&#xD;
&#xD;
          -  Diabetes or blood-glucose sensitivity&#xD;
&#xD;
          -  Any prior invasive cosmetic surgery to the waist or abdominal area, such as&#xD;
             liposuction.&#xD;
&#xD;
          -  Hernias or diastasis recti within the treatment area.&#xD;
&#xD;
          -  Concurrent, or within the last 6 months, participation in any clinical trial for&#xD;
             another device or drug.&#xD;
&#xD;
          -  Existing bacterial or viral infections (influenza, rhinovirus, hepatitis, pneumonia,&#xD;
             tuberculosis, and the like)&#xD;
&#xD;
          -  Presence of acne vulgaris, herpes zoster, psoriasis vulgaris, or similar skin&#xD;
             conditions in the treatment area.&#xD;
&#xD;
          -  Any type of cosmetic treatment to the target area within the last 6 months.&#xD;
&#xD;
          -  Implanted active medical device anywhere in the subject, or metallic or polymeric&#xD;
             implants in the vicinity of the treatment area.&#xD;
&#xD;
          -  Currently undergoing, or recently underwent, chemotherapy or radiation treatment.&#xD;
&#xD;
          -  Per the investigator's discretion, any physical or mental condition which may&#xD;
             compromise the patient's safety or welfare.&#xD;
&#xD;
          -  Failure to complete the study as outlined.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Just the Right Cruves</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <zip>84047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <results_first_submitted>November 6, 2020</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ultrasound</keyword>
  <keyword>Low-Frequency</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04206384/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04206384/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.&#xD;
Ultrasound: Ultimate Contour Body Sculpting Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.&#xD;
Ultrasound: Ultimate Contour Body Sculpting Device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>Inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.95" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.36" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Waist Circumference Change</title>
        <description>Change in measurable circumference of the patient's abdominal area from Baseline to immediately after the 4-week follow-up assessment (approximately 6 weeks from Baseline).</description>
        <time_frame>The difference between the circumference measurement immediately prior to the first treatment (Baseline) to immediately after the 4-week follow-up assessment (approximately 6 weeks from Baseline).</time_frame>
        <population>Participants who completed treatment process and follow-up visits as described.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.&#xD;
Ultrasound: Ultimate Contour Body Sculpting Device</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference Change</title>
          <description>Change in measurable circumference of the patient's abdominal area from Baseline to immediately after the 4-week follow-up assessment (approximately 6 weeks from Baseline).</description>
          <population>Participants who completed treatment process and follow-up visits as described.</population>
          <units>Inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pain</title>
        <description>Incidence of pain during each application of the device and/or immediately following each application of the device (up to 15 minutes after use of the device ceased).</description>
        <time_frame>Assessed during and immediately after (up to 15 minutes after use ceased) each application of the device, and at 1 week, 4 weeks, and 12 weeks post-treatment.</time_frame>
        <population>Assessment of participant during or after any treatment application.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.&#xD;
Ultrasound: Ultimate Contour Body Sculpting Device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain</title>
          <description>Incidence of pain during each application of the device and/or immediately following each application of the device (up to 15 minutes after use of the device ceased).</description>
          <population>Assessment of participant during or after any treatment application.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection and follow-up occurred over a space of up to 8 weeks.</time_frame>
      <desc>No difference in definition. Event collection consisted of enquiring of the participant any observations following application of the device. Participants were to keep a study diary and document any observations. Investigator reviewed study diaries and identified any comments that constitute an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.&#xD;
Ultrasound: Ultimate Contour Body Sculpting Device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in the ears</sub_title>
                <description>During application of the device, some participants reported hearing a ringing or buzzing in their ears, although the device or applicator handpiece were not generating an externally audible noise.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>Participant complained of vertigo when getting up from the treatment table following use of the device.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Participant developed constipation 2 days after a treatment session.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Participant described having a mild headache, the evening after a treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fatty Urine</sub_title>
                <description>Participant described seeing fatty or cloudy urine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <description>Participant developed a rash a day after a treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inflammation / Heat Sensation</sub_title>
                <description>Participant indicated feeling heat at the application site and/or presented with redness or inflammation of the treatment site.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the coronavirus (COVID-19) pandemic, the planned 12-week follow-up was conducted virtually. This prevented capture of the primary measurement at this timepoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>VP, Quality &amp; Regulatory</name_or_title>
      <organization>CAO Group</organization>
      <phone>801-256-9282</phone>
      <email>info@caogroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

